<?xml version="1.0" encoding="UTF-8"?>
<p class="p">This single-blind, parallel randomized clinical trial was authorized by the Ethics Committee of Tabriz University of Medical Sciences (code: TBZMED.REC.1394.576) on 26 November 2015, and was registered in the Iranian Registry of Clinical Trials (IRCT201509295563N7) on 9 January 2016. A total of 60 women with PCOS aged 18â€“35 years old with primary and secondary infertility, a body mass index (BMI) between 26.5 and 28.5 kg/m
 <sup class="sup">2</sup>, and willing to be pregnant were included in the study. The participants were from the Infertility Clinic, Alzahra Hospital, Tabriz, Iran, and contributed to the study for approximately nine months (from 16 January 2016 to 25 October 2016). The diagnosis of PCOS was based on Rotterdam criteria (2003), satisfying at least two out of three of the following criteria: oligomenorrhea /or amenorrhea, clinical /or biochemical sign of hyperandrogenism, and presence of PCOS by ultrasonography [
 <xref rid="B30-biomolecules-09-00215" ref-type="bibr" class="xref">30</xref>]. The criteria for inclusion were PCOS women diagnosed with primary or secondary infertility, aged between 18 and 35 years, and having a BMI &lt; 30. The exclusion criteria included the patients with diabetes mellitus, the use of medications such as those helping ovulation or insulin sensitizers, thyroid disorders, cholesterol-lowering drugs, smoking, current treatment of infertility, hypertension, cardiovascular diseases, Cushing syndrome, and allergy to spearmint, ginger, cinnamon, and 
 <italic class="italic">C. sinensis.</italic>
</p>
